The immunohistochemical detection of ATRX/DAXX downregulation, strongly correlates with ALT in tumor specimen of Pancreatic neuroendocrin tumors [65], in hepatic angiosarcomas [66] and leyomiosarcoma [67], suggesting that this complex could be employed in the clinical practice as a surrogate marker of ALT phenotype. The gene discussed is ATRX; the disease is liver angiosarcoma.